AR081575A1 - Formas de dosificacion oral de bendamustina y su uso terapeutico - Google Patents
Formas de dosificacion oral de bendamustina y su uso terapeuticoInfo
- Publication number
- AR081575A1 AR081575A1 ARP110101916A ARP110101916A AR081575A1 AR 081575 A1 AR081575 A1 AR 081575A1 AR P110101916 A ARP110101916 A AR P110101916A AR P110101916 A ARP110101916 A AR P110101916A AR 081575 A1 AR081575 A1 AR 081575A1
- Authority
- AR
- Argentina
- Prior art keywords
- bendamustine
- pharmaceutically acceptable
- minutes
- pharmaceutical composition
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición farmacéutica de administración oral que comprende bendamustina como ingrediente activo, o un éster, una sal o un solvato de ésta, y un excipiente farmacéuticamente aceptable, que presenta una disolución de la bendamustina de al menos 60% en 20 minutos, 70% en 40 minutos y 80% en 60 minutos, medida con un aparato con paletas a 50 rpm, de acuerdo con la Farmacopea Europea, en 500 mI de un medio de disolución a un pH de 1,5, y donde el excipiente farmacéuticamente aceptable es un agente tensioactivo no iónico farmacéuticamente aceptable seleccionado del grupo que consiste en el aceite de ricino polietoxilado o un derivado de éste y un copolímero de bloques de óxido de etileno y óxido de propileno, o un sacárido farmacéuticamente aceptable seleccionado del grupo que consiste en uno o más monosacáridos, disacáridos, oligosacáridos, oligosacáridos cíclicos, polisacáridos y alcoholes de sacáridos, donde la proporción en peso entre el ingrediente activo y los uno o más excipientes sacáridos se halla en el rango de 1:1-5. Uso de una composición farmacéutica como la anterior en el tratamiento oral de una condición médica seleccionada entre la leucemia linfocítica crónica, la leucemia linfocítica aguda, la leucemia mielocítica crónica, la leucemia mielocítica aguda, la enfermedad de Hodgkin, el linfoma no Hodgkin, el mieloma múltiple, el cáncer de mama, el cáncer de ovario, el cáncer de las células pulmonares pequeñas y el cáncer de las células pulmonares no pequeñas. Uso de una composición farmacéutica como la anterior en un régimen de dosificación que comprende al menos la administración de una dosis de entre 100 y 600 mg/m2 de bendamustina por persona el día 1 y el día 2, opcionalmente de una dosis i.v. u oral de entre 50 y 150 mg/m2 de un corticosteroide los días 1 a 5, y opcionalmente de una dosis apropiada de un agente activo adicional seleccionado del grupo que consiste en un anticuerpo específico para CD20, un derivado de antraciclina, un vinca alcaloide o un derivado de platina; y la repetición de dicho régimen de dosificación entre 4 y 15 veces, después de intervalos de entre dos y cuatro semanas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10005762 | 2010-06-02 | ||
EP11075046 | 2011-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR081575A1 true AR081575A1 (es) | 2012-10-03 |
Family
ID=44261747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110101916A AR081575A1 (es) | 2010-06-02 | 2011-06-02 | Formas de dosificacion oral de bendamustina y su uso terapeutico |
Country Status (25)
Country | Link |
---|---|
US (2) | US20130209558A1 (es) |
EP (1) | EP2575785B1 (es) |
JP (2) | JP2013527206A (es) |
KR (1) | KR101830147B1 (es) |
CN (1) | CN103037852B (es) |
AR (1) | AR081575A1 (es) |
AU (1) | AU2011260614B2 (es) |
BR (1) | BR112012030658B1 (es) |
CA (1) | CA2800277A1 (es) |
CL (1) | CL2012003340A1 (es) |
CO (1) | CO6640268A2 (es) |
DK (1) | DK2575785T3 (es) |
EA (1) | EA027786B1 (es) |
ES (1) | ES2935792T3 (es) |
FI (1) | FI2575785T3 (es) |
IL (2) | IL223309B (es) |
JO (1) | JO3659B1 (es) |
MX (1) | MX2012013873A (es) |
MY (1) | MY173881A (es) |
NZ (1) | NZ603874A (es) |
PL (1) | PL2575785T3 (es) |
SG (1) | SG185794A1 (es) |
TW (1) | TWI556819B (es) |
WO (1) | WO2011151086A1 (es) |
ZA (1) | ZA201208822B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2911427T3 (es) * | 2011-09-18 | 2022-05-19 | Euro Celtique Sa | Composición farmacéutica que comprende un inhibidor HDAC y un ciclopolisacárido |
TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
EP2641592A1 (en) | 2012-03-23 | 2013-09-25 | Salmon Pharma GmbH | Pharmaceutical formulation comprising bendamustine |
DK2656843T3 (en) | 2012-04-26 | 2015-04-20 | Helmut Schickaneder | Esters of bendamustine and related compounds, and medical use thereof |
RU2015132902A (ru) * | 2013-01-07 | 2017-02-09 | Сам-А Фарм. Ко., Лтд. | Новый быстрорастворимый состав гранул с улучшенной растворимостью |
EP3043648B1 (en) * | 2013-08-27 | 2023-09-20 | Vasilios VOUDOURIS | Bendamustine pharmaceutical compositions |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
CN110772480B (zh) * | 2016-03-25 | 2022-05-17 | 南京百劲企业管理咨询有限公司 | 苯达莫司汀药剂组合物及应用 |
AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
CN112848583B (zh) * | 2020-12-31 | 2022-08-05 | 雅达环保科技(玉田)有限公司 | 一种阻燃保温板及其制备方法 |
WO2023113650A1 (ru) * | 2021-12-15 | 2023-06-22 | Владимир Евгеньевич НЕБОЛЬСИН | Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE159289C (es) * | 1903-10-08 | 1905-03-16 | ||
US20040072889A1 (en) * | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
DE19826517B4 (de) * | 1998-06-15 | 2006-03-23 | Baxter Healthcare S.A. | Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20030105141A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
DE10304403A1 (de) * | 2003-01-28 | 2004-08-05 | Röhm GmbH & Co. KG | Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung |
US7423004B2 (en) | 2003-01-31 | 2008-09-09 | Smithkline Beecham Corporation | Solid dispersion compositions |
EP1605916A4 (en) * | 2003-02-12 | 2012-02-22 | R & P Korea Co Ltd | SOLUBENT SOLVENT SYSTEM WITH SOLUBLE PEEL WITH IMPROVED ELUTION RATE |
EP1610820B2 (en) * | 2003-04-04 | 2013-08-21 | Genentech, Inc. | High concentration antibody and protein formulations |
JP2008519047A (ja) | 2004-11-05 | 2008-06-05 | セフアロン・インコーポレーテツド | 癌処置 |
US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
US8105625B2 (en) * | 2007-04-05 | 2012-01-31 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
CN101801188A (zh) | 2007-07-12 | 2010-08-11 | 特拉加拉医药品公司 | 治疗癌症、肿瘤和肿瘤相关性疾病的方法和组合物 |
EP2215211A1 (en) * | 2007-11-06 | 2010-08-11 | 3M Innovative Properties Company | Processing device tablet |
AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
PL2299987T3 (pl) * | 2008-06-06 | 2018-08-31 | Boehringer Ingelheim International Gmbh | Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu |
US8349353B2 (en) | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
UA107186C2 (xx) * | 2008-12-03 | 2014-12-10 | Тверді форми дозування бендамустину | |
SI2367542T1 (sl) * | 2008-12-03 | 2014-05-30 | Astellas Deutschland Gmbh | Oralne dozirne oblike bendamustina |
US20100273730A1 (en) * | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
CN102413816A (zh) * | 2009-04-28 | 2012-04-11 | 赛福伦公司 | 苯达莫司汀的口服制剂 |
US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
-
2011
- 2011-05-31 JO JOP/2011/0179A patent/JO3659B1/ar active
- 2011-06-01 NZ NZ603874A patent/NZ603874A/en unknown
- 2011-06-01 FI FIEP11727917.4T patent/FI2575785T3/fi active
- 2011-06-01 BR BR112012030658-8A patent/BR112012030658B1/pt not_active IP Right Cessation
- 2011-06-01 DK DK11727917.4T patent/DK2575785T3/da active
- 2011-06-01 MX MX2012013873A patent/MX2012013873A/es unknown
- 2011-06-01 PL PL11727917.4T patent/PL2575785T3/pl unknown
- 2011-06-01 ES ES11727917T patent/ES2935792T3/es active Active
- 2011-06-01 SG SG2012087797A patent/SG185794A1/en unknown
- 2011-06-01 AU AU2011260614A patent/AU2011260614B2/en active Active
- 2011-06-01 EA EA201291249A patent/EA027786B1/ru unknown
- 2011-06-01 EP EP11727917.4A patent/EP2575785B1/en active Active
- 2011-06-01 WO PCT/EP2011/002763 patent/WO2011151086A1/en active Application Filing
- 2011-06-01 US US13/701,228 patent/US20130209558A1/en not_active Abandoned
- 2011-06-01 CN CN201180038034.4A patent/CN103037852B/zh not_active Expired - Fee Related
- 2011-06-01 MY MYPI2012701043A patent/MY173881A/en unknown
- 2011-06-01 CA CA2800277A patent/CA2800277A1/en not_active Abandoned
- 2011-06-01 JP JP2013512794A patent/JP2013527206A/ja active Pending
- 2011-06-01 KR KR1020127033703A patent/KR101830147B1/ko active IP Right Grant
- 2011-06-02 TW TW100119386A patent/TWI556819B/zh active
- 2011-06-02 AR ARP110101916A patent/AR081575A1/es not_active Application Discontinuation
-
2012
- 2012-11-22 ZA ZA2012/08822A patent/ZA201208822B/en unknown
- 2012-11-27 IL IL223309A patent/IL223309B/en active IP Right Grant
- 2012-11-29 CL CL2012003340A patent/CL2012003340A1/es unknown
- 2012-12-10 CO CO12223428A patent/CO6640268A2/es not_active Application Discontinuation
-
2015
- 2015-03-18 US US14/661,693 patent/US10485787B2/en active Active
-
2016
- 2016-06-03 JP JP2016112212A patent/JP6259490B2/ja active Active
-
2020
- 2020-02-06 IL IL272501A patent/IL272501A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR081575A1 (es) | Formas de dosificacion oral de bendamustina y su uso terapeutico | |
Israel et al. | Phytochemicals: Current strategies for treating breast cancer | |
RU2743643C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
CO6400185A2 (es) | Formas de dosificación sólida de bendamustina | |
RU2567044C2 (ru) | Ингибиторы 1 киназы контрольной точки клеточного цикла для усиления днк-повреждающих агентов | |
CL2016001411A1 (es) | Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina. | |
ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
JP2016526039A5 (es) | ||
AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
AR078224A1 (es) | Composicon para el tratamiento del cancer de prostata | |
CA2712747A1 (en) | Combinatory cancer treatment | |
AR081835A1 (es) | Formas de dosificacion oral de bendamustina | |
JP2019530706A5 (es) | ||
ES2656913T3 (es) | Endrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes | |
BR112019015023A2 (pt) | Intensificadores de canibalismo celular para uso para sensibilizar tumores para terapia por radiação | |
Jia-Yi et al. | Effect and mechanism of Qishen Yiqi Pills on adriamycin-induced cardiomyopathy in mice | |
PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
AR075866A1 (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica. | |
CN103877005A (zh) | 一种复方奥氮平皮下埋植缓释剂 | |
RU2013105513A (ru) | Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи | |
RU2346692C2 (ru) | Применение 9-оксоакридин-10-уксусной кислоты, ее солей и сложных эфиров в комбинированной терапии рака яичников, способ лечения и наборы | |
RU2013150335A (ru) | Применение секнидазола для лечения одонтогенных инфекций | |
Chico et al. | Quinine for the treatment of malaria in pregnancy | |
Secades et al. | Role of citicoline on the treatment of ischemic stroke: a formal and cumulative meta-analysis | |
US9974776B2 (en) | Estrogen receptor beta agonists for use in treating mesothelioma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |